MetaVia’s (MTVA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of MetaVia (NASDAQ:MTVA) in a research report report published on Friday,Benzinga reports.

A number of other equities research analysts have also weighed in on the company. Wall Street Zen raised MetaVia to a “sell” rating in a research note on Saturday, June 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research note on Friday, April 24th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $20.00.

MetaVia Stock Up 2.9%

NASDAQ:MTVA traded up $0.05 during midday trading on Friday, hitting $1.78. The company had a trading volume of 129,086 shares, compared to its average volume of 216,302. The company has a market capitalization of $9.18 million, a PE ratio of -0.34 and a beta of 0.97. MetaVia has a 52-week low of $0.97 and a 52-week high of $19.03. The stock’s fifty day moving average price is $1.90 and its 200-day moving average price is $2.65.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). As a group, research analysts forecast that MetaVia will post -2.78 earnings per share for the current year.

Institutional Trading of MetaVia

An institutional investor recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new position in MetaVia Inc. (NASDAQ:MTVA) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent SEC filing. 1.37% of the stock is currently owned by hedge funds and other institutional investors.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.